The pharmaceutical giant Novartis and the Copenhagen-based company Dawn Health are cooperating on a platform development for the management of chronic diseases such as high blood pressure, multiple sclerosis, cardiovascular diseases and breast cancer. The platform will include patient apps, symptom monitoring, digital biomarkers, clinical decision support and virtual clinic services. Recently, a large number of strategic partnerships between digital health and pharmaceutical companies have become known that are digitally advancing the management of chronic diseases.
LINK